Funding
← Back to your selection

Pfizer Ventures

Activity from announced rounds

Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026

Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.

Recorded funding activity

TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.

Sources
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$189.5M
3 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1
Undisclosed1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
TwoStep Therapeutics

A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.

$62.5MSeries A
Role not disclosed
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed